Tmunity Therapeutics, a Philadelphia, PA-based T-cell immunotherapy company, closed a $75m Series B financing.
The round was led by Andreessen Horowitz with participation from a16z’s Cultural Leadership Fund, Westlake Village BioPartners, Gilead Sciences, The University of Pennsylvania, Be The Match BioTherapies and BrightEdge, the philanthropic impact fund of the American Cancer Society. As part of the Series B financing, Jorge Conde, General Partner at a16z, will join Tmunity Therapeutics’ Board of Directors.
The company, which has raised $231m in totoal funding, intends to use the funds to continue to fund ongoing and planned research, clinical development of product candidates, the continued build-out of its proprietary, vertically-integrated viral vector and cell therapy product manufacturing, working capital and other general purposes.
Led by Usman “Oz” Azam, MD, President and Chief Executive Officer, Tmunity is a clinical-stage biotherapeutics company focused on delivering next-generation T-cell immunotherapy to patients with devastating diseases. Integrating a foundational collaboration with the University of Pennsylvania (Penn) with the scientific, clinical, and manufacturing expertise, and the track record of its founders (Carl June, MD; Bruce Blazar, MD; Bruce Levine, PhD; Yangbing Zhao, MD, PhD; Jim Riley, PhD; and Anne Chew, PhD), Tmunity is developing a diversified portfolio of novel treatments that exhibit control over T-cell activation and direction in the body, with a focus in cancer and three programs currently in clinic development.
The company utilizes laboratories and production facilities at Penn and its own dedicated cGMP manufacturing facility in East Norriton, PA, to pursue process improvement and production scale-up in support of clinical development of its T-cell therapies.